Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Classical pathology and mutational load of breast cancer - integration of two worlds.

Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz JK, Györffy B, Dietel M, Loibl S, Weichert W, Stenzinger A.

J Pathol Clin Res. 2015 Jul 20;1(4):225-38. doi: 10.1002/cjp2.25. eCollection 2015 Oct.

2.

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment.

Budczies J, Pfarr N, Stenzinger A, Treue D, Endris V, Ismaeel F, Bangemann N, Blohmer JU, Dietel M, Loibl S, Klauschen F, Weichert W, Denkert C.

Oncotarget. 2016 Mar 15;7(11):13236-47. doi: 10.18632/oncotarget.7451.

3.

Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer.

Roßner F, Gieseler C, Morkel M, Royer HD, Rivera M, Bläker H, Dietel M, Schäfer R, Sers C.

Oncogenesis. 2016 Jan 18;5:e187. doi: 10.1038/oncsis.2015.51.

4.

Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.

Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI.

Cancer Res. 2016 Feb 15;76(4):796-804. doi: 10.1158/0008-5472.CAN-15-2298. Epub 2015 Dec 18.

5.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K.

Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429.

6.

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.

Arsenic R, Treue D, Lehmann A, Hummel M, Dietel M, Denkert C, Budczies J.

BMC Clin Pathol. 2015 Nov 18;15:20. doi: 10.1186/s12907-015-0020-6. eCollection 2015.

7.

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.

Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, García RC, Kerr KM, Lim E, López-Ríos F, Thunnissen E, Van Schil PE, von Laffert M.

Thorax. 2016 Feb;71(2):177-84. doi: 10.1136/thoraxjnl-2014-206677. Epub 2015 Nov 3. Review.

8.

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.

Arsenic R, Braicu EI, Letsch A, Dietel M, Sehouli J, Keilholz U, Ochsenreither S.

BMC Cancer. 2015 Oct 24;15:784. doi: 10.1186/s12885-015-1824-6.

9.

The combinatorial complexity of cancer precision medicine.

Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A.

Oncoscience. 2014 Jul 23;1(7):504-9. eCollection 2014.

10.

The landscape of metastatic progression patterns across major human cancers.

Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, Wolf T, Warth A, Dietel M, Anagnostopoulos I, Weichert W, Wittschieber D, Stenzinger A.

Oncotarget. 2015 Jan 1;6(1):570-83.

11.

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.

Poremba C, Uhlendorff J, Pfitzner BM, Hennig G, Bohmann K, Bojar H, Krenn V, Brase JC, Haufe F, Averdick M, Dietel M, Kronenwett R, Denkert C.

Virchows Arch. 2014 Oct;465(4):409-17. doi: 10.1007/s00428-014-1652-0. Epub 2014 Sep 14.

12.

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.

Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, Kaltenecker G, Rüdiger T, Pfitzner B, Kittel K, Fiedler B, Baumann K, Moll R, Dietel M, Eidtmann H, Thomssen C, Loibl S.

BMC Cancer. 2014 Jul 28;14:546. doi: 10.1186/1471-2407-14-546.

13.

Guidance for laboratories performing molecular pathology for cancer patients.

Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjö A, Rouleau E, Solé F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, Van Krieken JH; European Society of Pathology Task Force on Quality Assurance in Molecular Pathology; Royal College of Pathologists.

J Clin Pathol. 2014 Nov;67(11):923-31. doi: 10.1136/jclinpath-2014-202404. Epub 2014 Jul 10. Review.

14.

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.

Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel R, Thunnissen E.

Br J Cancer. 2014 Jul 15;111(2):413-20. doi: 10.1038/bjc.2014.353. Epub 2014 Jul 1.

15.

An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.

Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, Tubbs RR, Hirsch FR.

J Thorac Oncol. 2014 May;9(5):631-8. doi: 10.1097/JTO.0000000000000115.

16.

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.

Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, Kühn T, Diebold K, Untch M, Holms F, Blohmer JU, Habeck JO, Dietel M, Overkamp F, Krabisch P, von Minckwitz G, Denkert C.

PLoS One. 2013 Dec 2;8(12):e79775. doi: 10.1371/journal.pone.0079775. eCollection 2013.

17.

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions.

Müller BM, Keil E, Lehmann A, Winzer KJ, Richter-Ehrenstein C, Prinzler J, Bangemann N, Reles A, Stadie S, Schoenegg W, Eucker J, Schmidt M, Lippek F, Jöhrens K, Pahl S, Sinn BV, Budczies J, Dietel M, Denkert C.

PLoS One. 2013 Jun 27;8(6):e68252. doi: 10.1371/journal.pone.0068252. Print 2013.

18.

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.

Müller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C.

BMC Cancer. 2013 Apr 30;13:215. doi: 10.1186/1471-2407-13-215.

19.

CognitionMaster: an object-based image analysis framework.

Wienert S, Heim D, Kotani M, Lindequist B, Stenzinger A, Ishii M, Hufnagl P, Beil M, Dietel M, Denkert C, Klauschen F.

Diagn Pathol. 2013 Feb 27;8:34. doi: 10.1186/1746-1596-8-34.

20.

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.

Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S.

Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk